Literature DB >> 17934074

Clinical significance of human immunodeficiency virus type 1 replication fitness.

Carrie Dykes1, Lisa M Demeter.   

Abstract

The relative fitness of a variant, according to population genetics theory, is that variant's relative contribution to successive generations. Most drug-resistant human immunodeficiency virus type 1 (HIV-1) variants have reduced replication fitness, but at least some of these deficits can be compensated for by the accumulation of second-site mutations. HIV-1 replication fitness also appears to influence the likelihood of a drug-resistant mutant emerging during treatment failure and is postulated to influence clinical outcomes. A variety of assays are available to measure HIV-1 replication fitness in cell culture; however, there is no agreement regarding which assays best correlate with clinical outcomes. A major limitation is that there is no high-throughput assay that incorporates an internal reference strain as a control and utilizes intact virus isolates. Some retrospective studies have demonstrated statistically significant correlations between HIV-1 replication fitness and clinical outcomes in some patient populations. However, different studies disagree as to which clinical outcomes are most closely associated with fitness. This may be in part due to assay design, sample size limitations, and differences in patient populations. In addition, the strength of the correlations between fitness and clinical outcomes is modest, suggesting that, at present, it would be difficult to utilize these assays for clinical management.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17934074      PMCID: PMC2176046          DOI: 10.1128/CMR.00017-07

Source DB:  PubMed          Journal:  Clin Microbiol Rev        ISSN: 0893-8512            Impact factor:   26.132


  182 in total

1.  Fitness costs limit viral escape from cytotoxic T lymphocytes at a structurally constrained epitope.

Authors:  Fred W Peyerl; Heidi S Bazick; Michael H Newberg; Dan H Barouch; Joseph Sodroski; Norman L Letvin
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

2.  Early virological failure in treatment-naive HIV-infected adults receiving didanosine and tenofovir plus efavirenz or nevirapine.

Authors:  Agathe León; Esteban Martinez; Josep Mallolas; Montserrat Laguno; Jose Luis Blanco; Tomás Pumarola; Josep María Gatell
Journal:  AIDS       Date:  2005-01-28       Impact factor: 4.177

3.  Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: a case report.

Authors:  Martin Markowitz; Hiroshi Mohri; Saurabh Mehandru; Anita Shet; Leslie Berry; Roopa Kalyanaraman; Alexandria Kim; Chris Chung; Patrick Jean-Pierre; Amir Horowitz; Melissa La Mar; Terri Wrin; Neil Parkin; Michael Poles; Christos Petropoulos; Michael Mullen; Daniel Boden; David D Ho
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

Review 4.  Considerations in selecting protease inhibitor therapy.

Authors:  Brian A Boyle; Richard A Elion; Graeme J Moyle; Calvin J Cohen
Journal:  AIDS Rev       Date:  2004 Oct-Dec       Impact factor: 2.500

5.  Differences in the fitness of two diverse wild-type human immunodeficiency virus type 1 isolates are related to the efficiency of cell binding and entry.

Authors:  Andre J Marozsan; Dawn M Moore; Michael A Lobritz; Erika Fraundorf; Awet Abraha; Jacqueline D Reeves; Eric J Arts
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

6.  Diminished replicative fitness of primary human immunodeficiency virus type 1 isolates harboring the K65R mutation.

Authors:  Jan Weber; Bikram Chakraborty; Jitka Weberova; Michael D Miller; Miguel E Quiñones-Mateu
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

7.  Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase.

Authors:  L M Mansky; H M Temin
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

8.  Mode of dimerization of HIV-1 genomic RNA.

Authors:  G Awang; D Sen
Journal:  Biochemistry       Date:  1993-10-26       Impact factor: 3.162

9.  Replication-dependent 65R-->K reversion in human immunodeficiency virus type 1 reverse transcriptase double mutant K65R + L74V.

Authors:  Prem L Sharma; Viktoria Nurpeisov; Kimberly Lee; Sara Skaggs; Christina Amat Di San Filippo; Raymond F Schinazi
Journal:  Virology       Date:  2004-04-10       Impact factor: 3.616

10.  Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection.

Authors:  Bluma Brenner; Jean-Pierre Routy; Yudong Quan; Daniela Moisi; Maureen Oliveira; Dan Turner; Mark A Wainberg
Journal:  AIDS       Date:  2004-08-20       Impact factor: 4.177

View more
  28 in total

1.  Lower CD4 cell count and higher virus load, but not antiretroviral drug resistance, are associated with AIDS-defining events and mortality: an ACTG Longitudinal Linked Randomized Trials (ALLRT) analysis.

Authors:  Susan Swindells; Hongyu Jiang; A Lisa Mukherjee; Mark Winters; Ronald J Bosch; David Katzenstein
Journal:  HIV Clin Trials       Date:  2011 Mar-Apr

2.  Replication Capacity of Viruses from Acute Infection Drives HIV-1 Disease Progression.

Authors:  Philippe Selhorst; Carina Combrinck; Nonkululeko Ndabambi; Sherazaan D Ismail; Melissa-Rose Abrahams; Miguel Lacerda; Natasha Samsunder; Nigel Garrett; Quarraisha Abdool Karim; Salim S Abdool Karim; Carolyn Williamson
Journal:  J Virol       Date:  2017-03-29       Impact factor: 5.103

Review 3.  HIV-1 drug resistance mutations: an updated framework for the second decade of HAART.

Authors:  Robert W Shafer; Jonathan M Schapiro
Journal:  AIDS Rev       Date:  2008 Apr-Jun       Impact factor: 2.500

4.  Replication fitness of multiple nonnucleoside reverse transcriptase-resistant HIV-1 variants in the presence of etravirine measured by 454 deep sequencing.

Authors:  Chanson J Brumme; Kelly D Huber; Winnie Dong; Art F Y Poon; P Richard Harrigan; Nicolas Sluis-Cremer
Journal:  J Virol       Date:  2013-05-29       Impact factor: 5.103

5.  A systems analysis of mutational effects in HIV-1 protease and reverse transcriptase.

Authors:  Trevor Hinkley; João Martins; Colombe Chappey; Mojgan Haddad; Eric Stawiski; Jeannette M Whitcomb; Christos J Petropoulos; Sebastian Bonhoeffer
Journal:  Nat Genet       Date:  2011-03-27       Impact factor: 38.330

6.  Viral envelope is a major determinant of enhanced fitness of a multidrug-resistant HIV-1 variant.

Authors:  Hiroshi Mohri; Nicole Prada; Martin Markowitz
Journal:  J Acquir Immune Defic Syndr       Date:  2015-04-15       Impact factor: 3.731

7.  Ultrasensitive allele-specific PCR reveals rare preexisting drug-resistant variants and a large replicating virus population in macaques infected with a simian immunodeficiency virus containing human immunodeficiency virus reverse transcriptase.

Authors:  Valerie F Boltz; Zandrea Ambrose; Mary F Kearney; Wei Shao; Vineet N Kewalramani; Frank Maldarelli; John W Mellors; John M Coffin
Journal:  J Virol       Date:  2012-08-29       Impact factor: 5.103

8.  Only slight impact of predicted replicative capacity for therapy response prediction.

Authors:  Hendrik Weisser; André Altmann; Saleta Sierra; Francesca Incardona; Daniel Struck; Anders Sönnerborg; Rolf Kaiser; Maurizio Zazzi; Monika Tschochner; Hauke Walter; Thomas Lengauer
Journal:  PLoS One       Date:  2010-02-03       Impact factor: 3.240

9.  vFitness: a web-based computing tool for improving estimation of in vitro HIV-1 fitness experiments.

Authors:  Jingming Ma; Carrie Dykes; Tao Wu; Yangxin Huang; Lisa Demeter; Hulin Wu
Journal:  BMC Bioinformatics       Date:  2010-05-18       Impact factor: 3.169

10.  Diverse cross-reactive potential and Vbeta gene usage of an epitope-specific cytotoxic T-lymphocyte population in monkeys immunized with diverse human immunodeficiency virus type 1 Env immunogens.

Authors:  Sandrine L Hulot; Michael S Seaman; Pritha Sen; Patrick A Autissier; Edwin R Manuel; Norman L Letvin
Journal:  J Virol       Date:  2009-07-29       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.